Physician profile
Melissa Nihiser
NPI 1033458831
$3,694.99
in general payments reported to CMS, 2019-2025
32 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.60 · 2022: $447 · 2023: $1,248 · 2024: $1,256 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $621.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $354.65 | 2022-2024 | |
| Lilly USA, LLC | $336.82 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $282.08 | 2023-2024 | |
| Amgen INC. | $231.64 | 2022-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $187.21 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $185.98 | 2022-2025 | |
| Cvrx, INC. | $158.15 | 2025 | Barostim Neo System |
| Edwards Lifesciences Corporation | $120.52 | 2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.27 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.97 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $108.08 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $100.63 | 2022-2024 | Belsomra, Gardasil, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $90.02 | 2023-2024 | Rexulti |
| Dexcom, INC. | $83.71 | 2024 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $56.06 | 2023 | Gralise |
| Phathom Pharmaceuticals, INC. | $47.94 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $47.74 | 2023-2024 | |
| Renalytix Ai, INC. | $47.26 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $46.88 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $46.27 | 2023-2024 | Xarelto |
| Angiodynamics, INC. | $43.38 | 2025 | Auryon Laser System 100-120 Vac |
| Novartis Pharmaceuticals Corporation | $38.12 | 2023 | Leqvio |
| Actelion Pharmaceuticals US, INC. | $36.86 | 2025 | Opsumit |
| Xeris Pharmaceuticals, INC. | $32.52 | 2022-2023 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $31.53 | 2023-2024 | Nexletol |
| Genzyme Corporation | $28.10 | 2025 | |
| Axonics, INC. | $25.66 | 2023 | Axonics |
| Sumitomo Pharma America, INC. | $22.94 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $20.88 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $19.01 | 2023 | Farxiga |
| Boston Scientific Corporation | $16.06 | 2024 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Nihiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.